과민성 방광 치료 시장 : 병상 유형별, 연령층별 - 세계 예측(2024-2032년)

Global Overactive Bladder Treatment Market will achieve a 4.3% CAGR between 2024 and 2032, propelled by advancements in treatment options and increased research and development. Innovations in pharmaceuticals, such as the development of new medications and advanced neuromodulation techniques, provide patients with more effective and diverse treatment choices. Ongoing research into the underlying causes and management of OAB fuels the creation of improved therapies and interventions. This continuous progress enhances treatment efficacy, expands industry offerings, and meets the growing demand for effective OAB solutions.

For instance, in July 2024, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved vibegron (Obgemsa) for treating overactive bladder syndrome (OAB) symptoms in adult patients. This development introduces a new therapeutic option, enhancing the range of treatments available for managing OAB symptoms. The approval underscores ongoing innovation in the field, potentially driving market growth by meeting the demand for effective new treatments. It also reflects a broader commitment to addressing and improving care for patients with overactive bladder.

The overactive bladder treatment industry is divided based on the condition type, treatment type, age group, and region.

The 60 above segment will see a considerable surge by 2032, attributed to the higher prevalence of the condition among older adults. Age-related changes in bladder function and an increased incidence of related health issues contribute to a greater demand for effective treatment options. As this demographic grows, the need for specialized therapies tailored to the older population intensifies. This trend highlights the significant market potential within the 60 and above age group for targeted overactive bladder treatments.

The neuromodulation segment will garner notable gains by 2032, driven by its innovative approach to managing symptoms effectively. Techniques such as sacral nerve stimulation and percutaneous tibial nerve stimulation offer targeted relief by modulating nerve activity involved in bladder control. These advanced therapies provide vital benefits, including reduced side effects compared to traditional treatments. As demand for minimally invasive and effective solutions grows, neuromodulation's role in offering personalized, long-lasting relief drives its dominance in the industry.

Europe overactive bladder treatment market will secure a moderate CAGR through 2032, owing to its advanced healthcare infrastructure and high prevalence of the condition. The region's robust medical research capabilities and substantial investment in innovative treatments contribute to industry growth. Additionally, increasing awareness and access to specialized healthcare services support the demand for effective overactive bladder therapies. Europe's combination of sophisticated healthcare systems and active research makes it a key contributor to the global overactive bladder treatment industry.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of overactive bladder
    • 3.2.1.2 Growing aging population
    • 3.2.1.3 Increasing research investments and activities
    • 3.2.1.4 Growing awareness for early diagnosis and treatment
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Adverse effects associated with medications and treatment
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Porters analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Condition Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Neurogenic bladder overactivity
• 5.3 Idiopathic bladder overactivity

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Drug therapy
  • 6.2.1 Anticholinergics
  • 6.2.2 Beta-3 adrenoceptor agonists
• 6.3 Botox treatment
• 6.4 Neuromodulation
• 6.5 Other treatment types

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 18-30
• 7.3 31-50
• 7.4 51-60
• 7.5 60 above

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AbbVie Inc.
• 9.2 Astellas Pharma Inc.
• 9.3 Axonics, Inc.
• 9.4 BlueWind Medical
• 9.5 Cipla Ltd.
• 9.6 Endo International plc
• 9.7 Laborie
• 9.8 Lupin Ltd.
• 9.9 Medtronic plc
• 9.10 Merck & Co.
• 9.11 Pfizer Inc.
• 9.12 Sumitomo Pharma America, Inc. (Urovant Sciences)
• 9.13 Teva Pharmaceutical Industries Ltd.
• 9.14 Viatris Inc.
• 9.15 Zydus Lifesciences Ltd.